Perrigo

Perrigo Co. Plc engages in the provision of self-care products and over-the-counter (OTC) health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the following segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The CSCI segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Perrigo reports strong Q1 growth, faces challenges in product shortages

Perrigo's Q1 2023 performance showcased growth and margin expansion, with a focus on operational excellence. The company faces challenges with product shortages and declining national brand volumes but sees opportunities in pricing increases and supply chain optimization. By leveraging strengths in private label growth and strategic initiatives, Perrigo aims to deliver on guidance for the year.

Perrigo reports strong Q2 performance, eyes Opill launch success

Perrigo's Q2 2023 earnings call highlighted strong financial performance, strategic strengths, key challenges, and growth opportunities. The company is focused on sustainable growth, market differentiation, and leveraging its capabilities for success in the industry.

Perrigo reports solid Q3 earnings, navigates challenges for future growth

Perrigo's Q3 performance showcased growth in net sales and margin expansion, despite challenges in certain product segments. The company remains focused on margin improvement, supply chain optimization, and growth initiatives for future success. With revised outlooks and ongoing strategic efforts, Perrigo aims to navigate challenges and capitalize on growth opportunities.

Perrigo reports robust Q4 earnings, focuses on growth initiatives

Perrigo's Q4 2023 earnings call showcased strong financial performance, with notable growth in net sales and margins.
While facing challenges in its infant formula business, the company outlined remediation plans and expects recovery in the second half of 2024.
Opportunities lie in the launch of Opill, Project Energise, and a focus on strengthening the infant formula business.
Perrigo aims to drive growth by executing strategic initiatives and providing more clarity on growth perspectives during an upcoming Investor Day.

Perrigo reports Q1 challenges, Opill success, and growth opportunities

Perrigo faced challenges in net sales due to infant formula actions but showed strength in innovation and store brands.
Opportunities lie in adapting to retailer inventory changes and expected gross margin improvement in Q2.
The company remains on track to meet 2024 commitments with progress in infant formula recovery and successful product launches.
Analysts focused on infant formula progress, Opill revenue potential, and portfolio refinements during the call.

Perrigo reports Q2 resilience amidst challenges, eyes growth opportunities

Perrigo faced challenges in Q2 2024 with a decline in organic net sales, primarily due to infant formula and certain category sales. Despite this, the company showed resilience with growth in operating income and a focus on core segments. Opportunities lie in recovering share, enhancing marketing, and the potential for infant formula recovery.

Perrigo reports robust Q3 earnings, focuses on efficiency and growth

Perrigo's Q3 performance reflects a resilient financial position, marked by strong EPS growth and operational efficiency gains through cost-saving initiatives.
While facing challenges in net sales decline, the company's strategic focus on core business stabilization and efficiency improvements bodes well for long-term growth.
With a commitment to financial targets, Perrigo is poised to capitalize on opportunities for revenue diversification and market expansion, supported by a strengthened operational foundation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Perrigo Co. Plc engages in the provision of self-care products and over the counter health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The Consumer Self-Care International segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Perrigo (PRGO) reports encouraging second-quarter 2023 results. Management reaffirms the financial guidance for 2023.

Perrigo (PRGO) Beats on Q2 Earnings & Sales, Reiterates '23 View

The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Perrigo (PRGO) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Perrigo (PRGO) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.54 per share. This compares to earnings of $0.43 per share a year ago.

Perrigo (PRGO) Q2 Earnings and Revenues Beat Estimates

Achieved Year-Over-Year and Sequential Gross and Operating Margin Expansion Delivered Strong Operating Income and EPS Growth Reaffirming 2023 Outlook DUBLIN , Aug. 8, 2023 /PRNewswire/ --  Second Quarter 2023 Highlights: Second quarter net sales of $1.2 billion grew 6.4%, or 6.6% on a constant currency1 basis, versus the prior year quarter. Organic2 net sales grew 0.8%, including -2.7 percentage points from purposeful SKU prioritization actions to enhance margins as part of the Company's Supply Chain Reinvention Program.

Perrigo Reports Second Quarter Fiscal Year 2023 Financial Results From Continuing Operations

DUBLIN, Ireland , Aug. 2, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.273 per share, payable on September 19, 2023, to shareholders of record on September 1, 2023. About Perrigo Perrigo Company, plc (NYSE: PRGO) is a leading provider of Consumer Self Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.

PERRIGO ANNOUNCES QUARTERLY DIVIDEND

DUBLIN , July 25, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its second quarter 2023 financial results on Tuesday, August 8, 2023, and will host a conference call beginning at 8:30 A.M. (EST). Separately, President and CEO, Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Canaccord Genuity 43rd Annual Growth Conference in Boston on Wednesday, August 9 th at 10:30 A.M.

Perrigo to Release Second Quarter 2023 Financial Results and Present at an Industry Growth Conference

Perrigo's birth control pill, Opill, can now be sold without a prescription. It'll likely start to nibble on the market shares of most other contraceptive methods.

With a Big Catalyst in Hand, Is Perrigo Company a Buy?

Following the FDA approval, Perrigo's (PRGO) Opill is the first ever over-the-counter birth control pill. The drug will be made available in the United States early next year.

Perrigo (PRGO) Gets FDA Nod for First OTC Birth Control Pill

Perrigo (NYSE: PRGO ) stock is rising on Friday as investors react to the company's over-the-counter birth control pill getting FDA approval. This is a major win for Perrigo stock as it marks the first time that the FDA has approved a daily over-the-counter birth control pill.

PRGO Stock Alert: Perrigo Climbs on Landmark FDA Birth Control Decision

The FDA just approved the first over-the-counter birth control pill -- Perrigo's Opill. There could be a significant demand for the OTC oral contraceptive.

FDA Approves Over-the-Counter Birth Control Pill. Is the Pill Maker's Stock Set to Soar?

The Food and Drug Administration approved the first over-the-counter birth-control pill, significantly expanding access to contraception among women across the U.S.

FDA Approves First Over-the-Counter Birth-Control Pill

Perrigo Company (NYSE:PRGO) shares moved higher after the provider of over-the-counter (OTC) health and wellness solutions announced that its daily progestin-only contraceptive pill Opill has been approved by the U.S. Food and Drug Administration (FDA) for OTC use, allowing women to purchase birth control without a prescription for the first time in the country.

Perrigo shares rise as Opill birth control pill is approved for over-the-counter use in US

GlaxoSmithKline

Patterson Companies

Finding a qualified financial advisor doesn't have to be hard. SmartAsset's free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes.

3 Healthcare Stocks to Buy Amid Market Volatility

Perrigo's Opill could significantly expand access to contraception, especially for younger women who often face logistical barriers to get birth control.

FDA approves first over-the-counter birth control pill

The drug will be available in store and online at retailers across the country 'early in the first quarter of 2024,' the company says.

FDA Approves First Over-The-Counter Birth Control Pill in U.S. Perrigo Stock Jumps.

Perrigo Co. PLC's stock PRGO, -0.78% soared 6% in premarket trade Thursday, after the company said the U.S. Food and Drug Administration has approved its over-the-counter daily oral contraceptive. The move was expected after an FDA advisory panel voted overwhelmingly in favor of the pill called opill, which is the first OTC contraceptive to be approved in the U.S.

Perrigo's stock soars 6% after FDA approves its over-the-counter daily oral contraceptive

The U.S. Food and Drug Administration on Thursday approved the over-the-counter use of Perrigo's contraceptive drug, making it the first non-prescription birth control pill in the United States.

US FDA approves Perrigo's contraceptive pill for over-the-counter use

DUBLIN , July 13, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, announced today that the U.S. Food and Drug Administration (FDA) approved Opill®, a progestin-only daily oral contraceptive, for over-the-counter (OTC) use for all ages. Opill® is the first ever birth control pill available over the counter in the United States.

Perrigo Announces U.S. FDA Approval for Opill® OTC Daily Oral Contraceptive

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Perrigo (PRGO) Stock?

Are Investors Undervaluing Perrigo (PRGO) Right Now?

The mean of analysts' price targets for Perrigo (PRGO) points to a 49.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Perrigo (PRGO)? Wall Street Analysts Think 49.5%

Perrigo is repositioning itself as an exclusively consumer-facing over-the-counter brand, streamlining its sales process, and expanding its market through acquisitions. PRGO's Opill contraceptive is expected to receive FDA approval for OTC usage, potentially boosting the company's net sales in the women's health and contraceptive category. Despite concerns about debt levels, PRGO's 3.31% dividend yield and position as one of the largest consumer staples manufacturers make it an attractive recession-resistant dividend investment in my view.

Perrigo Outlook Healed By Repositioning

Perrigo Co. Plc PRGO, +0.51% on Thursday named Patrick Lockwood-Taylor as its new president and chief executive officer as of June 30. Lockwood-Taylor previously worked in dual roles at Bayer AG as president of the Bayer U.S. business, as well as regional president of consumer health North America.

Perrigo hires Bayer's ex-U.S. head as new CEO

DUBLIN , June 8, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced the appointment of industry professional Patrick Lockwood-Taylor as its new President, Chief Executive Officer and member of the Board of Directors, effective June 30, 2023. Mr. Lockwood-Taylor joins Perrigo from Bayer AG, where he served a dual role as President of the approximately $15 billion revenue Bayer U.S. business and Regional President of Consumer Health North America, achieving high single-digit growth during his tenure.

Perrigo Appoints Patrick Lockwood-Taylor as President and CEO

The heavy selling pressure might have exhausted for Perrigo (PRGO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

News for Perrigo Stock (PRGO)